Project Code: 10459245
Faculty: Liggins Institute
Department: Liggins Institute
Main Supervisor: Professor Caroline Crowther
Application open date: 15 Jan 2020
Application deadline: 28 Feb 2022
Enrolment information: NZ Citizens, NZ Permanent Residents, International
Gestational diabetes mellitus (GDM) is a major health problem globally. Within New Zealand one in every 11 pregnant women or over 5,500 women annually are affected. There is global controversy as to the precise degree of glucose intolerance required for the diagnosis of GDM, leading to the use of several different diagnostic criteria worldwide. Similarly there is controversy as to the optimal glycaemic targets to use for women with gestational diabetes.
The GEMS Trial is assessing the effects of the new IADPSG criteria compared with current recommended New Zealand criteria on maternal and infant health outcomes.
The TARGET Trial has assessed the use of tight with less tight treatment targets for women with gestational diabetes on maternal and infant health.
This research project will compare health care utilisation between the two diagnostic criteria used in the GEMS Trial and also the two treatment targets used in the TARGET Trial.
Background in a health discipline with an interest in health economics or an economics background. Examples include (but are not limited to) health economics, public health, epidemiology, medicine and midwifery. Knowledge of the New Zealand health care system is required.
To establish the cost effectiveness of the new IADPSG criteria for the diagnosis of GDM, compared with current recommended New Zealand criteria.
To establish the cost effectiveness of the use of tighter treatment targets with less tight treatment targets for women with GDM.
Here is more information about the GEMS Trial:
Here is more information about the TARGET Trial: